Complications associated with intraperitoneal chemotherapy catheters

被引:75
作者
Makhija, S
Leitao, M
Sabbatini, P
Bellin, N
Almadrones, L
Leon, L
Spriggs, DR
Barakat, R
机构
[1] Mem Sloan Kettering Canc Ctr, Dept Gynecol Surg, New York, NY 10021 USA
[2] Mem Sloan Kettering Canc Ctr, Dept Biostat, New York, NY 10021 USA
[3] Mem Sloan Kettering Canc Ctr, Dept Dev Chemotherapy, New York, NY 10021 USA
[4] Beth Israel Hosp, Dept Obstet & Gynecol, New York, NY 10003 USA
[5] Our Lady Mercy Med Ctr, Dept Obstet & Gynecol, New York, NY 10466 USA
关键词
D O I
10.1006/gyno.2000.6108
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose. The goal of this work was to determine the complication rate and any predisposing risk factors associated with subcutaneous intraperitoneal (ip) catheters used in the treatment of patients with advanced ovarian cancer. Methods. We retrospectively reviewed the charts of 301 patients who had a subcutaneous Bardport catheter placed for administration of ip chemotherapy at Memorial Sloan-Kettering Cancer Center (MSKCC) from December 1989 to May 1997. Results. Thirty (10%) patients were identified as having catheter-related complications, with 19(6.3%) experiencing inflow obstruction and 11 (3.6%) experiencing infection. Only 21 of 301 (7%) required cessation of chemotherapy prior to its expected completion, with 14 (4.6%) occurring in the malfunction group and 7 (2.3%) in the infection group. Three hundred thirteen patients received an ip catheter; however, 12 patients who received their ip chemotherapy elsewhere were excluded when determining the complication rate. Overall, 218 of 313 (69.6%) catheters were placed at the time of laparotomy, 61 of 313 (19.5%) catheters were placed at the time of laparoscopy, and 34 of 313 (10.9%) were placed as a separate procedure. In the malfunction group, 18 of 19 (94.7%) patients had their catheters placed at the time of laparotomy, none were placed at the time of laparoscopy, and 18 of 19 (5.3%) was placed as a separate procedure. In the infection group, 8 of 11 (72.7%) catheters were placed at laparotomy, 2 of 11 (18.3%) were placed at the time of laparoscopy, and 1 of 11 (9.0%) was placed as a separate procedure, Complications occurred in 3 of 54 (5.5%) patients who received platinum alone, 11 of 134 (8.2%) who received platinum in combination, 2 of 43 (4.7%) who received paclitaxel alone, 13 of 61 (21.3%) who received mitoxantrone alone or in combination, and 1 of 9 (11.1%) who received other regimens. Conclusion. Subcutaneous ip catheters are associated with a lower rate of catheter-related complications than previously reported, perhaps due in part to both avoiding insertion of ip catheters at the time of bowel surgery and placing ip catheters at the time of laparoscopy. (C) 2001 Academic Press.
引用
收藏
页码:77 / 81
页数:5
相关论文
共 22 条
[1]   Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer [J].
Alberts, DS ;
Liu, PY ;
Hannigan, EV ;
OToole, R ;
Williams, SD ;
Young, JA ;
Franklin, EW ;
ClarkePearson, DL ;
Malviya, VK ;
DuBeshter, B ;
Adelson, MD ;
Hoskins, WJ .
NEW ENGLAND JOURNAL OF MEDICINE, 1996, 335 (26) :1950-1955
[2]   A phase II trial of intraperitoneal cisplatin and etoposide as consolidation therapy in patients with stage II-IV epithelial ovarian cancer following negative surgical assessment [J].
Barakat, RR ;
Almadrones, L ;
Venkatraman, ES ;
Aghajanian, C ;
Brown, C ;
Shapiro, F ;
Curtin, JP ;
Spriggs, D .
GYNECOLOGIC ONCOLOGY, 1998, 69 (01) :17-22
[3]  
Barakat RR, 2000, CURR CLIN ONCOL, V2, P167
[4]   TECHNICAL ASPECTS OF INTRAPERITONEAL CHEMOTHERAPY IN ABDOMINAL CARCINOMATOSIS [J].
BRALY, P ;
DOROSHOW, J ;
HOFF, S .
GYNECOLOGIC ONCOLOGY, 1986, 25 (03) :319-333
[5]   INTRAPERITONEAL CHEMOTHERAPY - ANALYSIS OF COMPLICATIONS WITH AN IMPLANTED SUBCUTANEOUS PORT AND CATHETER SYSTEM [J].
DAVIDSON, SA ;
RUBIN, SC ;
MARKMAN, M ;
JONES, WB ;
HAKES, TB ;
REICHMAN, B ;
ALMADRONES, L ;
CHAPMAN, D ;
LEWIS, JL ;
HOSKINS, WJ .
GYNECOLOGIC ONCOLOGY, 1991, 41 (02) :101-106
[6]   Pharmacokinetic problems in peritoneal drug administration: Tissue penetration and surface exposure [J].
Dedrick, RL ;
Flessner, MF .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1997, 89 (07) :480-487
[7]   A phase II study of intraperitoneal cisplatin and thiotepa in residual ovarian carcinoma. A gynecologic oncology group study [J].
Feun, LG ;
Blessing, JA ;
Major, FJ ;
DiSaia, PJ ;
Alvarez, RD ;
Berek, JS .
GYNECOLOGIC ONCOLOGY, 1998, 71 (03) :410-415
[8]   PHASE-I FEASIBILITY AND PHARMACOLOGICAL STUDY OF WEEKLY INTRAPERITONEAL PACLITAXEL - A GYNECOLOGIC-ONCOLOGY-GROUP PILOT-STUDY [J].
FRANCIS, P ;
ROWINSKY, E ;
SCHNEIDER, J ;
HAKES, T ;
HOSKINS, W ;
MARKMAN, M .
JOURNAL OF CLINICAL ONCOLOGY, 1995, 13 (12) :2961-2967
[9]   Phase II trial of intraperitoneal cisplatin and mitoxantrone in patients with persistent ovarian cancer [J].
Husain, A ;
Sabbatini, P ;
Spriggs, D ;
Fennelly, D ;
Aghajanian, C ;
Barakat, R ;
Curtin, J ;
Venkatraman, E ;
Hoskins, W ;
Markman, M .
GYNECOLOGIC ONCOLOGY, 1999, 73 (01) :96-101
[10]   Cancer statistics, 1999 [J].
Landis, SH ;
Murray, T ;
Bolden, S ;
Wingo, PA .
CA-A CANCER JOURNAL FOR CLINICIANS, 1999, 49 (01) :8-31